Ebrahim Variava

Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

Francesca Conradie, Tatevik R. Bagdasaryan, Pauline Howell et al. · New England Journal of Medicine · 2022 · 507 citations · Full text

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt et al. · The Lancet · 2015 · 248 citations

Pulmonary Tuberculosis, Phase 2B, Tuberculosis Prevention +9

High Nasopharyngeal Pneumococcal Density, Increased by Viral Coinfection, Is Associated With Invasive Pneumococcal Pneumonia

Nicole Wolter, Stefano Tempia, Cheryl Cohen et al. · The Journal of Infectious Diseases · 2014 · 193 citations · Full text

Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study

Waasila Jassat, Caroline Mudara, Lovelyn Ozougwu et al. · The Lancet Global Health · 2021 · 175 citations · Full text

Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study

Waasila Jassat, Cheryl Cohen, Stefano Tempia et al. · The Lancet HIV · 2021 · 174 citations · Full text